Back to Trades
Other4
Astria Therapeutics, Inc.
ATXS
Total Value
$468.2K
Company Information
- Company Name
- Astria Therapeutics, Inc.
- Ticker Symbol
- ATXS
- CIK
- 0001454789
Insider Information
- Name
- BATE KENNETH
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Jan 23, 2026
- Transaction Date
- Jan 23, 2026
- Accession Number
- 0000905148-26-000312
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jan 23, 2026 | Derivative | 16,666 | — | Disposition | — |
| Jan 23, 2026 | Derivative | 8,333 | $3.00 | Disposition | $25.0K |
| Jan 23, 2026 | Derivative | 14,100 | $11.35 | Disposition | $160.0K |
| Jan 23, 2026 | Derivative | 14,100 | $9.18 | Disposition | $129.4K |
| Jan 23, 2026 | Derivative | 26,550 | $5.79 | Disposition | $153.7K |
Footnotes
- (F1)These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
- (F2)Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.